Literature DB >> 16797594

The morphological basis of mental dysfunction in Parkinson's disease.

K A Jellinger1.   

Abstract

Mental dysfunction including dementia in Parkinson's disease (PD), the incidence of which averages 20-40%, is suggested to have six-fold lifetime risk compared to age-matched controls. It is caused by a variety of functional and pathological lesions ranging from damage to subcortical-cortical networks to cortical and limbic Lewy body and neuritic Alzheimer pathologies, the relationship and impact of which are still under discussion. Based on two consecutive autopsy series of PD, with prevalence of cognitive impairment of 33% to 35.7%, its essential morphological changes and their impact on the natural history (survival) are discussed. Whereas cortical Lewy body stages 5 and 6 without additional pathologies only rarely were associated with dementia, around 20% of demented PD cases were classified as dementia with Lewy bodies (DLB) with variable degrees of Alzheimer (AD) pathology, and around one third showed severe neuritic AD lesions which occurred in PD patients with later disease onset and significantly shorter survival. Frequent close relations in the severity between alpha-synuclein and tau-pathologies suggest synergistic reaction and common underlying pathogenesis of both lesions. Clinico-pathological studies in PD showed a significantly negative relation between cognitive impairment and neuritic AD lesions somewhat different from that in AD, suggesting that neuritic AD pathology, either alone or in combination with cortical and limbic Lewy bodies, are major causes of mental and cognitive dysfunction in PD.

Entities:  

Mesh:

Year:  2006        PMID: 16797594     DOI: 10.1016/j.jns.2006.05.002

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  15 in total

1.  Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA).

Authors:  Richard J O'Brien; Susan M Resnick; Alan B Zonderman; Luigi Ferrucci; Barbara J Crain; Olga Pletnikova; Gay Rudow; Diego Iacono; Miguel A Riudavets; Ira Driscoll; Donald L Price; Lee J Martin; Juan C Troncoso
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 2.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

3.  A model-based quantification of action control deficits in Parkinson's disease.

Authors:  Mathieu Servant; Nelleke van Wouwe; Scott A Wylie; Gordon D Logan
Journal:  Neuropsychologia       Date:  2018-01-29       Impact factor: 3.139

4.  DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.

Authors:  Sara Batelli; Diego Albani; Raffaela Rametta; Letizia Polito; Francesca Prato; Marzia Pesaresi; Alessandro Negro; Gianluigi Forloni
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240

5.  Morphometry of the human substantia nigra in ageing and Parkinson's disease.

Authors:  Gay Rudow; Richard O'Brien; Alena V Savonenko; Susan M Resnick; Alan B Zonderman; Olga Pletnikova; Laura Marsh; Ted M Dawson; Barbara J Crain; Mark J West; Juan C Troncoso
Journal:  Acta Neuropathol       Date:  2008-02-23       Impact factor: 17.088

6.  Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates.

Authors:  Kelvin L Chou; Adrienne Lenhart; Robert A Koeppe; Nicolaas I Bohnen
Journal:  Parkinsonism Relat Disord       Date:  2014-07-19       Impact factor: 4.891

Review 7.  [Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors].

Authors:  I Liepelt; W Maetzler; H-P Blaicher; T Gasser; D Berg
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

8.  Cerebral amyloid angiopathy in Lewy body disease.

Authors:  K A Jellinger; J Attems
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

9.  Neocortex and allocortex respond differentially to cellular stress in vitro and aging in vivo.

Authors:  Jessica M Posimo; Amanda M Titler; Hailey J H Choi; Ajay S Unnithan; Rehana K Leak
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

10.  The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease.

Authors:  Elena M Vazey; Gary Aston-Jones
Journal:  Front Behav Neurosci       Date:  2012-07-25       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.